This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SHAPIRO, G. Articles by EVRON, S. Search for Related Content PubMed PubMed Citation Articles by SHAPIRO, G. Articles by EVRON, S.

A Novel Use of Spironolactone: Treatment of Hirsutism

Departments of Endocrinology and Metabolism Gynecology and Obstetrics
Hadassah University Hospital Jerusalem, Israel

Address requests for reprints to: German Shapiro, M.D., Division of Endocrinology and Metabolism, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, Colorado 80262.

An excess of androgens is the recognized cause of hirsutism in women. In this study, the antiandrogenic properties of spironolactone were tested clinically in 30 hirsute women. The drug was administered from the 4th to the 22nd day of each menstrual cycle. The moderate side effects in no case forced interruption of the treatment. Hair growth diminished substantially in 23 of the patients, the effect becoming evident 3-5 months after the commencement of treatment. Serum testosterone concentrations decreased in all patients, and estradiol increased in 25 women. Our data suggest that the antiandrogenic properties of spironolactone render it a suitable agent in the treatment of hirsutism.

Received January 4, 1980.

This article has been cited by other articles:

				Endocrinology & Metabolism News, August 2005 J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 17a - 17a. [Full Text] [PDF]

				P. Moghetti, R. Castello, N. Zamberlan, M. Rossini, D. Gatti, C. Negri, F. Tosi, M. Muggeo, and S. Adami Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1250 - 1254. [Abstract] [Full Text]

				S. Venturoli, O. Marescalchi, F. M. Colombo, S. Macrelli, B. Ravaioli, A. Bagnoli, R. Paradisi, and C. Flamigni A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1304 - 1310. [Abstract] [Full Text]

				E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba Androgens and Therapeutic Aspects of Antiandrogens in Women Reproductive Sciences, July 1, 1995; 2(4): 577 - 592. [Abstract] [PDF]

				R. S. RITTMASTER and D. L. LORIAUX Hirsutism Ann Intern Med, January 1, 1987; 106(1): 95 - 107. [Abstract] [PDF]

				A. W. Lucky Topical Antiandrogens: What Use in Dermatology? Arch Dermatol, January 1, 1985; 121(1): 55 - 56. [Abstract] [PDF]

				A. Weissmann, J. Bowden, B. L. Frank, S. N. Horwitz, and P. Frost Antiandrogenic Effects of Topically Applied Spironolactone on the Hamster Flank Organ Arch Dermatol, January 1, 1985; 121(1): 57 - 62. [Abstract] [PDF]

				S. S. Braithwaite and R. Jabamoni Hirsutism Arch Dermatol, April 1, 1983; 119(4): 279 - 284. [Abstract] [PDF]

				D. C. Cumming, J. C. Yang, R. W. Rebar, and S. S. C. Yen Treatment of Hirsutism With Spironolactone JAMA, March 5, 1982; 247(9): 1295 - 1298. [Abstract] [PDF]